.
In 1991 the NIH Consensus Conference on Acoustic Neuroma recommended another change to terminology. As the tumours are composed of schwann cells and typically involve the vestibular rather than the acoustic branch of the eighth cranial nerve, the term vestibular schwannoma rather than acoustic neuroma is suggested. We have therefore adopted this term.
As early as 1937 it was suggested NF2 could be divided into a severe and mild form.14 Recent studies have again drawn attention to this,'5 recommending the severe form should be called Wishart, with early onset bilateral vestibular schwannomas and multiple other tumour types, and the mild form be called Gardner type, with usually only late onset bilateral vestibular schwannoma. It has also been suggested that the family reported by Lee and Abbott'6 with multiple meningiomas as a major feature may be a third subtype.
Our interest in NF2 arose from genetic linkage studies and from the setting up of a neurofibromatosis register in Manchester in 1988 which led us to meet many subjects with Prevalence was calculated from all affected persons in the population of the North West Regional Health Authority, which was 4016 100 on prevalence day (1 June 1990). This gave a minimum prevalence of 19/ 4 016 100, that is 0 47 per 100 000 (4.7/106) of the population. The true prevalence is likely to be much higher as this figure includes only those who have a formal diagnosis of NF2.
Mean age at diagnosis in 110 subjects throughout the UK was 27-55 years and the severity of the condition results in early death in the majority of cases. Disease course from onset of symptoms averages 18-5 years,5 but in 22 cases in the UK the duration from diagnosis averaged only 8-09 years. Including the living cases, mean actuarial survival from diagnosis was 15 years. It would be logical to assume a greater degree of diagnostic delay among new mutations, especially as 13/56 familial cases were diagnosed asymptomatically. Including the asymptomatic cases as zero delay from onset of symptoms, the mean delay was 4-91 years in familial cases compared to 6-28 years in sporadic cases.
In the North West Region there were 27 asymptomatic offspring of affected cases at 50% prior risk. A further case at 50% prior risk from a family outside the region but resident in Manchester was added. Analysis of the at risk offspring using age at onset data ( The diagnostic prevalence would underestimate birth incidence because of the late age at presentation and the early expected death.
Death occurred at a mean age of 38-4 years in 37 cases, although mean actuarial survival was There appeared to be a marked degree of heterogeneity within NF2. Our pedigrees confirmed previous reports of marked interfamilial variation of disease; presentations within a family were relatively uniform although with some variation in age of presentation. There were two broad types of families.
( years respectively when corrected for year of birth and taken from the Registrar General's population data. This difference is not significant.
PARENTAL EFFECT ON SEVERITY
The mean age at first symptom or diagnosis in 36 maternally inherited cases was 18-17 years (SD 8-84, SE 1V47, median 18). The mean age in paternally inherited cases was 24-5 years (SD 11-83, SE 2-65, median . The difference in average age of onset of 6-33 years was significant (p = 0-026). There was a general impression of a worse clinical course in maternally inherited cases and average age at death in six cases was 24-33 years, compared to 39-33 in three paternally inherited cases.
Discussion
A population based study of NF2 in the UK has identified 150 cases from 91 families. Segregation analysis confirmed the expected autosomal dominant single gene mode of transmission. There is almost complete penetrance by the age of 60, although a broader definition than the NIH consensus criteria is required.23 There were no cases of affected sibs born to apparently normal parents and no cases of proven non-penetrance within families. One 67 year old obligate carrier resident in New Zealand has had two affected daughters, and although he has required a hearing aid for some years has only recently had investigations to confirm his diagnosis. The only case not to be confirmed was a 36 year old obligate carrier who inherited the gene from her mother. She has had two affected children, but died of a myocardial infarction at the age of 36 with no suspicious features of NF2. One case of probable non-penetrance was reported by Young et al,24 although she died in her early fifties without specific investigation. Kanter et aF also confirmed autosomal dominant inheritance in nine kindreds they studied personally and 15 published ones. A further two possible cases of non-penetrance were alluded to, but no information on age was given. Penetrance is likely therefore to be close to 100% by 60, especially if modern diagnostic imaging (MRI with gadolinium enhancement) is used to confirm the diagnosis. Although we have drawn attention to the heterogeneity in NF2 the evidence for two subtypes as described recently is still not overwhelming.'5 Some cases are very difficult to classify if they have a single meningioma in addition to vestibular schwannomas, while other cases with late onset may have multiple meningiomas. Classifying the condition purely on age at onset is clearly artificial, especially in view of the maternal gene effect. In view of the recent molecular analysis in myotonic dystrophy,25 another mechanism which has to be considered to explain variable age at onset is anticipation. As so few multigeneration families were identified in the present study, this issue is difficult to address. It is of interest that in the initial report of the largest NF2 family reported to date, Gardner and In contrast to the huge families reported from the USA,35 there were only two families with more than five affected cases. The first with nine known cases has been reported before.7 The second has eight cases in three generations, although three cases are outside the UK. There was no strong support for advanced paternal age as a mechanism to support the relatively high figure for mutation rate. Further studies are certainly needed as there was some suggestion of an effect from the increase in expected age of the fathers of just under a year and the skew towards the later pregnancies in the birth order data. The figure for mutation rate of 6-5 x 10-6 is less than that in NFI (3-1 to 10.4 x 10-5),30 but greater than in von Hippel-Lindau disease (4-4 x 10-6).31
There have been no previous studies that have looked at genetic fitness. We were sur-prised by the relatively normal level of fitness in NF2 calculated by comparing unaffected sibs; however, fitness is only measurable in people old enough to be diagnosed. Early age at onset in several cases clearly reduces fitness but as these cases remain young their data could not influence the calculations. Sibs may also reduce their families voluntarily because of the known genetic mechanism. The methods of Tanaka'920 rely on high levels of certainty of the diagnosis; this is approached but certainly not complete at 15 years of age. However, the younger cases are accounted for and it is therefore felt to be more accurate. The reduced fitness in males as compared to females could well be partially explained by the later expected age at marriage and first birth in males.
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